PYX Resources: Achieving volume and diversification milestones. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
The institutional investors will be more here today imho... 400p is easy and bare minimum expectation today
Why not.. global pandemic and people dying ... even a scent of a decent test or vaccine will send this into space. Good share, great RNS, pleased with the cov2 sars testing.
Very low free float . Demand will be high for this .
Massive news
I think this is massive news because it gives the concentration of antibodies it’s not just a yes or no it
“IDS shall sell, market and support this Test on a global basis.”
Shares tightly held .
Could easily see 500p plus today
Hope not, i want to get a few more . Still NT to buy. Off the radar for now
hopefully see 400 or 500p today
Looking forward to the press coverage
Jaap Stuut, CEO of IDS commented
"We are pleased that our collaboration with Technogenetics has achieved the important milestone of CE-marking a quantitative, fully automated SARS-CoV-2 antibody test running on the IDS-iSYS analyser. We anticipate launching this assay throughout Europe later this month. IDS has increased production levels of its analysers, and we have sufficient inventory levels to facilitate higher analyser placement levels driven by new customers wishing to run the Test."
NT to buy all the way today. This could be seriously undervalued at the moment. Less than 60 million
off the radar! Immunodiagnostic Systems Holdings plc (IDS), a specialty solution provider to the clinical laboratory diagnostic market, announces a new automated COVID-19 IgG assay (The Test) has achieved CE marking and is expected to be available for sale by the end of this month.
The Test, which arises from the partnership between IDS and Technogenetics, is designed to run on the automated IDS-iSYS analyser. Today IDS and Technogenetics reached a commercial agreement under which IDS shall sell, market and support this Test on a global basis. For territories which do not accept CE marked products, the requisite regulatory approvals will be required.
Significant Shareholders
Company Name
Number of ordinary shares of 2p each
Percentage of issued share capital
Forum European Smallcaps GmbH
989,876
3.52%
Forum Venture Capital GmbH
6,936,188
24.67%
Axxion SA
2,795,252
9.94%
Frankfurter Investmentgesellschaft mit variablem Kapital (SICAV)
2,419,648
8.61%
Schroders plc
3,267,802
11.62%
Polar Capital European Forager Fund Ltd
1,143,572
4.07%
Shareholder Value Beteiligungen AG
1,645,000
5.85%
70% of the shares are tightly held here
could really do another 100% today - antibodies test kits
For a long time diagnostics companies have been the Cinderella of the health sector: largely lowly-rated and neglected compared to drug developers etc. ... seen as almost a bit 'boring' compared to 'sexier' shares.
But with the coronavirus pandemic, that's now starting to change.
And I believe that we're now moving into a new era where these type stocks could become some of the most sought after on the market.
And as there's not that many of them around, supply and demand dictates that they could become very highly-valued indeed.
In contrast to IDH, some of the more speculative POTENTIAL game changers that investors are chasing may never actually work, and their share prices will crash accordingly.
What type would Warren Buffett choose? -
"I would rather be certain of a good result than hopeful of a great one."
http://www.quoteswise.com/warren-buffett-quotes-5.html
That said, IDH could potentially get involved in some 'sexier' COVID-19 business too.
It's spoken in the past about making acquisitions, and has nearly £28M. of cash for both this and new product development.
This could give it the best of both worlds.
And unlike ODX (Omega Diagnostics), there's no risk here of a deeply-discounted placing.
Either way, IDH deserves a re-rating in the current environment, and one should be forthcoming shortly.
Immunodiagnostic's current COVID-19 offering is a 'picks & shovels' play.
And remember where that phrase comes from
During the California Gold rush in the 19th century the most reliable way to get rich was reportedly to sell picks and shovels etc to the gold prospectors, rather than actually staking a claim.
"ELISA
... The enzyme-linked immunosorbent assay (ELISA) ... has been used as a diagnostic tool in medicine, plant pathology, and biotechnology, as well as a quality control check in various industries.
In the most simple form of an ELISA, antigens from the sample are attached to a surface. Then, a matching antibody is applied over the surface so it can bind to the antigen. This antibody is linked to an enzyme, and in the final step, a substance containing the enzyme's substrate is added. The subsequent reaction produces a detectable signal, most commonly a color change. ..."
https://en.wikipedia.org/wiki/ELISA
Mass diagnostic testing SHOULD be a game changer in the fight against coronavirus, but there's a global shortage of production capability for this.
IDH is helping to address this, so this SHOULD be a game changer for the company.
Indeed it's a major, lasting business opportunity for IDH, which is clearly moving fast to address this opportunity.
For multiple existing partners, and multiple new partners:
17th Apr 2020 4:35 pm RNS FY20 Trading Update
" ... We are offering our production facilities, and sales network, to several new and existing partners who are in the process of developing COVID-19 test kits. ..."
https://www.lse.co.uk/rns/IDH/fy20-trading-update-ls1laez9k3328x5.html
From the Immunodiagnostics Systems website:
"Manufacturing Support for COVID-19
Manufacturing Support
As the world struggles to contain the novel coronavirus (COVID-19) outbreak, it becomes clear that diagnostics test availability is a key constraint. To support our healthcare systems with this challenge, we need to rapidly move production resources into this area.
We at Immunodiagnostic Systems (IDS) want to play a part in the global effort fighting this pandemic. Therefore, we would like to offer our expertise and support in manufacturing ELISA kits for those companies with a COVID-19 diagnostic test that need more production capacity.
What we can provide
IDS is a leading in vitro diagnostic solution provider to the clinical laboratory market. We develop, manufacture and market innovative immunoassays and automated immunoanalyser technologies to provide improved diagnostic outcomes for patients.
We can offer large scale ELISA plate production, from initial formulation to packaging, labelling and shipment in our ISO 13485 and cGMP qualified facilities in Italy and the United Kingdom.
If you would like to learn more about how we can support your manufacturing efforts or require further information, please contact us on info@idsplc.com.
Let’s work together and make the world a safer place."
https://www.idsplc.com/uncategorised/covid19support/
IDH is a very substantial company, which is looking massively undervalued given the current shortage of COVID-19 testing capacity.
Here are the IDH figures:
Full year revenue for year ending 30.3.20: £39.3M. (an increase on 2019).
Cash at 31.3.20: £27.6M. (an increase on the year).
https://www.lse.co.uk/rns/IDH/fy20-trading-update-ls1laez9k3328x5.html
Current market cap. at 225p: £64.76M.
Less cash, = £37.16M. for the business above cash levels.
I.e. a revenue multiple of under one times revenue.
Omega Diagnostics (ODX) in comparison:
Half year revenue of £4.46M., a fall from previous first half.
As at 30.9.19: No net cash. Net current liabilities £3M.
Half year loss of £0.29M.
https://www.lse.co.uk/rns/ODX/interim-results-q4qktr6c1xzv3zc.html
Current market cap. at 32p: £48.58M.
I.e. a revenue multiple of over five times annualised revenue.
IDH is a former 20-bagger: rising from below 60p in 2005 to above 1,200p in 2011.
And it has plenty of facilities and cash to help address the COVID-19 testing shortage.
This could fuel another great period of share price performance.
Omega Diagnostics (ODX) has been doing rather well recently, multibagging from 7.625p at the start of this month to its current s.p. of 31p.
Fueled by announcements that it is to manufacture COVID-19 tests.
And IDH looks like it will also be entering into such agreements shortly, judging from its recent trading update.
But the market doesn't seem to have picked up on this yet.
Probably because IDH is currently 'under the radar screen' of most investors, and the RNS was released after close on Friday (17th. April).
17th Apr 2020 4:35 pm RNS FY20 Trading Update
" ... Cash position
Closing cash and cash equivalents were £27.6m at 31 March 2020 (31 March 2019: £27.7m). ...
Looking forward
So far in April 2020 we have seen a reduction in revenue versus the same period last year, caused by a reduction in routine medical testing in hospitals and laboratories as their focus has been on COVID-19 treatment and testing. IDS intend to take appropriate action, including utilising the various schemes available from governments to provide business support, to minimise our costs during this period of uncertainty. From a liquidity perspective, IDS is in a very strong position with cash holdings of almost £28m.
We are offering our production facilities, and sales network, to several new and existing partners who are in the process of developing COVID-19 test kits. ... "
https://www.lse.co.uk/rns/IDH/fy20-trading-update-ls1laez9k3328x5.html
Know how you feel nmh19 ..
If i was starting again think id just go for EFTs
Well at least my loss in NIPT is less than if I had held on here.. Flippin eck I do pick emmmm...
November 27, 2015 10:09 pm Small-cap Week, November 28 Bryce Elder Bryce Elder Immunodiagnostic Systems faces challenging market Competition from bigger companies in its market is proving a huge challenge for Immunodiagnostic Systems, writes Chris Tighe.
Glad I jumped ship....
Looks like they were. Ah well think I will look at NIPT now. Good luck all ..
Bought am concerned there may well be more bad news relating to sales. Why tell us now???? Are mgt setting the scene?? Anyway too risky for me right now. GLA